A Phase II, Open-Label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)
Latest Information Update: 02 Aug 2022
At a glance
- Drugs Muscle-derived autologous stem cell therapy Bioheart (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms SEISMIC
- Sponsors Bioheart
- 25 Apr 2014 New source identified and integrated (ISCTN: Current Controlled Trials)
- 18 Feb 2014 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials
- 03 Dec 2013 New trial record